Łuszczycowe zapalenie stawów: badanie fazy III leku adalimumab i risankizumab
Open-label, randomized, assessor-blinded, efficacy, safety, tolerability, and pharmacokinetics study of subcutaneous risankizumab with an adalimumab reference arm in children…